14593973|t|Memantine for dementia?
14593973|a|Memantine (Ebixa--Lundbeck Ltd), an oral medicine, is available in the UK for treating "patients with moderately severe to severe Alzheimer's disease". It differs from other licensed dementia medicines in that it is an N-methyl-D-aspartate (NMDA) receptor antagonist. The company has claimed that, with memantine therapy, "improvements in activities of daily living help patients to maintain a degree of independence and be easier to care for, potentially avoiding the need for nursing home care". We assess the efficacy of memantine for dementia and discuss its place in the management of patients with Alzheimer's disease.
14593973	0	9	Memantine	Chemical	MESH:D008559
14593973	14	22	dementia	Disease	MESH:D003704
14593973	24	33	Memantine	Chemical	MESH:D008559
14593973	112	120	patients	Species	9606
14593973	154	173	Alzheimer's disease	Disease	MESH:D000544
14593973	207	215	dementia	Disease	MESH:D003704
14593973	327	336	memantine	Chemical	MESH:D008559
14593973	395	403	patients	Species	9606
14593973	548	557	memantine	Chemical	MESH:D008559
14593973	562	570	dementia	Disease	MESH:D003704
14593973	614	622	patients	Species	9606
14593973	628	647	Alzheimer's disease	Disease	MESH:D000544
14593973	Negative_Correlation	MESH:D008559	MESH:D000544
14593973	Negative_Correlation	MESH:D008559	MESH:D003704

